ravoxertinib   Click here for help

GtoPdb Ligand ID: 9229

Synonyms: example 39 [WO2013130976] | GDC-0994
PDB Ligand
Compound class: Synthetic organic
Comment: Ravoxertinib (GDC-0994) is an orally available, small molecule selective inhibitor of extracellular signal-regulated kinase 1/2 (ERK1/2) in early clinical development [1]. It is compound 22 in [1]. ERK1 is formally known as mitogen-activated protein kinase 3 (MAPK3) and ERK2 as mitogen-activated protein kinase 1 (MAPK1). GDC-0994 is example 39 claimed in patent WO2013130976 [2].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 2
Rotatable bonds 6
Topological polar surface area 97.86
Molecular weight 440.12
XLogP 3.65
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES OCC(n1ccc(cc1=O)c1ccnc(n1)Nc1ccnn1C)c1ccc(c(c1)F)Cl
Isomeric SMILES OC[C@@H](n1ccc(cc1=O)c1ccnc(n1)Nc1ccnn1C)c1ccc(c(c1)F)Cl
InChI InChI=1S/C21H18ClFN6O2/c1-28-19(5-8-25-28)27-21-24-7-4-17(26-21)13-6-9-29(20(31)11-13)18(12-30)14-2-3-15(22)16(23)10-14/h2-11,18,30H,12H2,1H3,(H,24,26,27)/t18-/m1/s1
Bioactivity Comments
In addition to ERKs 1 and 2, a kinase profile screen revealed that GDC-0994 inhibited CHK2 and PrKX by >90% at 1μM [1].
Selectivity at enzymes
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
mitogen-activated protein kinase 3 Primary target of this compound Hs Inhibitor Inhibition 8.2 – 8.5 pIC50 - 1-2
pIC50 8.2 – 8.5 (IC50 6.1x10-9 – 3.3x10-9 M) [1-2]
mitogen-activated protein kinase 1 Primary target of this compound Hs Inhibitor Inhibition 7.8 – 8.5 pIC50 - 1-2
pIC50 7.8 – 8.5 (IC50 1.55x10-8 – 3.1x10-9 M) [1-2]